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Necrotizing enterocolitis (NEC) is the most devastating gastrointestinal disease of prematurity. Although the precise cause is not well understood, the main risk factors thought
to contribute to NEC include prematurity, formula feeding, and bacterial colonization.
Recent evidence suggests that NEC develops as a consequence of intestinal hyperresponsiveness to microbial ligands upon bacterial colonization in the preterm infant,
initiating a cascade of aberrant signaling events, and a robust pro-inflammatory mucosal
immune response. We now have a greater understanding of important mechanisms of
disease pathogenesis, such as the role of cytokines, immunoglobulins, and immune
cells in NEC. In this review, we will provide an overview of the mucosal immunity of
the intestine and the relationship between components of the mucosal immune system
involved in the pathogenesis of NEC, while highlighting recent advances in the field that
have promise as potential therapeutic targets. First, we will describe the cellular components of the intestinal epithelium and mucosal immune system and their relationship to
NEC. We will then discuss the relationship between the gut microbiota and cell signaling
that underpins disease pathogenesis. We will conclude our discussion by highlighting
notable therapeutic advancements in NEC that target the intestinal mucosal immunity.
Keywords: necrotizing enterocolitis, innate immunity, mucosa, intestine, toll-like receptor 4, human milk
oligosaccharide, microbiota, prematurity
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Necrotizing enterocolitis (NEC) is notably the most lethal gastrointestinal disease of premature
infants. The disease prevalence is approximately 7% of infants born between 500 and 1,500 g in the
United States and Canada (1–3). Unfortunately, both the treatment approach and mortality have
remained unchanged for decades with a mortality rate as high as 42% (4). At the same time, NEC represents a significant economic burden on the health system with an estimated annual cost upwards of
one billion dollars in the United States (2, 5–7). These challenges fuel the need to understand disease
pathogenesis so as to develop novel therapeutic and preventative strategies. Presently, it is believed
that the immature intestine of premature infants exists in a hyper-active state due to abnormal
bacterial colonization, which ultimately results in a robust inflammatory response and impairment
of intestinal perfusion, thereby predisposing infants to NEC (2, 7, 8). Current research suggests the
intestinal immune system is intricately involved in this process, which is comprised of the intestinal
epithelium, immune cells, and commensal bacteria that maintain gastrointestinal homeostasis. Here,
we will review the current knowledge of intestinal mucosal immunity in relation to NEC. First, we
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will discuss the cell types that comprise the intestinal immune
system with attention to how these cells are involved in NEC.
We will then describe the role of the innate immune system with
specific attention to toll-like receptor 4 (TLR4) signaling in the
pathogenesis of NEC. We will then review the role of gut microbiota in our current understanding of this disease. Finally, we will
describe advancements in potential treatment strategies rooted in
our current understanding of the relationship between mucosal
immunity and the development of NEC.

(MHC) I and II molecules and non-classical MHC molecules,
allowing IECs to process and present antigens to the immune
cells of the intestine (21, 22). In doing so, there is a direct communication between the antigens within the lumen and the cells
of the lamina propria (Figure 1). Accordingly, enterocytes are
vital cells of the epithelium with the roles in the maintenance of
the gut barrier and commensal bacteria, absorption of nutrients,
and communication with the immune cells of the lamina propria.

Goblet Cells

CELLS OF THE INTESTINAL
IMMUNE SYSTEM

Goblet cells are particularly important with their role in generating the mucus layer of the intestine, preventing the interaction
between pathogenic bacteria and the epithelium, while providing support for commensal bacteria, antimicrobial peptides
(AMPs), and secretory immunoglobulin A (IgA) (23). Moreover,
goblet cells are also capable of delivering luminal antigens to
a subset of underlying dendritic cells (DCs), CD103+ lamina
propria DCs, which have tolerogenic properties, thereby assisting with the maintenance of commensal bacteria and intestinal
homeostasis (24).
Goblet cell differentiation is determined by the activity of
the Notch signaling pathway (25). Sodhi et al. (26) determined
that the innate immune receptor TLR4 regulates Notch signaling
and subsequent goblet cell development in the small intestine,
such that TLR4 signaling prevented goblet cell differentiation
independent from the influence of the microbiota. Furthermore,
Notch signaling was found to be increased in mice as well as
premature infants with NEC, whereas inhibition of the Notch
pathway led to an increased number of goblet cells and attenuated experimental NEC in mice (26). This study highlights the
regulation by TLR4 and Notch signaling in NEC pathogenesis.
Goblet cells secrete glycoproteins called mucins, of which, the
Muc2 mucin is of critical importance in maintaining an inner
mucus layer impervious to pathogenic bacteria, while simultaneously creating an outer mucus layer and providing an ideal habitat
for commensal bacteria (27). Notably, ileal Muc2 is decreased in
NEC and depletion of intestinal goblet cells increases susceptibility and severity of experimental NEC (28, 29). This subsequent
decrease in mechanical defenses increases the vulnerability of the
epithelium to pathogenic bacteria (26, 30), which can be further
exacerbated by decreased intestinal motility in the setting of
prematurity (31, 32). Abnormal goblet cell function is implicated
in the development of NEC and mechanisms to enhance goblet
cell production and/or function may provide a unique way to
prevent the disease.

In order to understand the pathogenesis of NEC, it is important
to appreciate the role of the immune system in the maintenance of
gastrointestinal homeostasis. We will first describe the role of epithelium and immune cells in mucosal immunity and then describe
their role in the development of NEC with specific attention to the
interplay of these cell types and the signaling pathways involved.

The Intestinal Epithelium

The epithelium represents the first layer of defense, comprised
of at least seven differentiated cell types that together maintain
barrier integrity and provide defense against pathogens with the
presence of tight junctions (9). The epithelium has two distinct
structures: the villus and the crypt. The villus contains enterocytes, goblet cells, enteroendocrine cells, and tuft cells, whereas
the crypt houses transit amplifying cells, Paneth cells, and stem
cells (Figure 1) (10). Stem cells expressing leucine-rich containing
G protein-coupled receptor 5 (Lgr5) are capable of generating all
cell types of the epithelium (11, 12). Together, these cells comprise
the epithelium, which we will now discuss in further detail.

Enterocytes

Enterocytes (IECs) are the predominant absorptive cells of the
epithelium defined by the presence of microvilli, but the role of
enterocytes is not limited to nutrient absorption; rather, they are
important cells in the preservation of intestinal integrity and
mucosal immunity (13–16). IECs, as the most numerous cells of
the epithelium, provide the physical barrier between the lumen
of the gastrointestinal tract and the lamina propria via the maintenance of tight junctions (14). They originate from within the
intestinal crypts and migrate along the villi, at which point they
undergo apoptosis, renewing the epithelium every 3–5 days in a
continuous cycle of IEC proliferation, migration, and apoptosis
in mouse studies (17). This cycle is crucial for intestinal homeostasis; however, aberrancy in this process can lead to disastrous
effects, such as bacterial translocation, which we will discuss in
the context of NEC in a later section (18). IECs are notable for the
presence of several pattern-recognition receptors (PRRs), such as
toll-like receptors (TLRs) and nucleotide-binding oligomerization
domains (NODs), thereby aiding in the clearance of pathogenic
bacteria while maintaining a population of commensal bacteria
(15, 16, 19, 20). We will describe TLRs and NODs more extensively in a later section with specific attention to the relationship
between TLR4 expression by enterocytes and gut barrier integrity. Moreover, IECs also express major histocompatibility class

Frontiers in Pediatrics | www.frontiersin.org

Paneth Cells

Paneth cells also provide a unique source of protection in the
maintenance of the intestinal barrier. Paneth cells produce AMPs,
lysozyme, secretory phospholipase A2, C-lectin RegIIIγ, α- and
β-defensins, and angiogenin-4 to protect the host from pathogenic
bacteria while shaping the composition of the microbiota (33, 34).
Paneth cells and their AMPs, particularly α-defensins, have been
implicated in diseases of the intestine through the use of several
animal models (33). One noteworthy study utilized two genetic
mouse models to study the role of α-defensins, including DEFA5expressing transgenic mice and also mice that are deficient in
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Figure 1 | The neonatal intestinal immune system and its interaction in the pathogenesis of necrotizing enterocolitis (NEC). (A) The intestinal mucosal
immune system is comprised of the cells of the epithelium, immune cells, and commensal bacteria. The epithelium consists of villi and crypts. Enterocytes, goblet
cells, enteroendocrine cells, and tuft cells exist within the villi, whereas Paneth cells and stem cells occupy the base of the crypts. Immune cells consist of
intraepithelial lymphocytes, T regulatory cells (Tregs), T cells, B cells, macrophages, and dendritic cells, which reside predominantly in the lamina propria underlying
the epithelium. Commensal bacteria inhabit the lumen of the gut, which constantly interact with the epithelium and immune cells to help maintain protection against
pathogenic bacteria. (B) In NEC, lipopolysaccharide from Gram-negative bacteria interact with toll-like receptor 4 (TLR4) expressed by predominantly by
enterocytes, which results in the breakdown of the gut barrier, allowing for pathogenic bacterial translocation. A pro-inflammatory response follows resulting in
increased production of pro-inflammatory cytokines (IL-6, IL-8, and TNF) as well as increased Th17 cells and decreased Tregs. The combination of these cellular
responses with TLR4 signaling results in a profound inflammatory response and subsequently NEC.

matrix metalloproteinase 7 (MMP7), which is required to activate
α-defensins (35). Using 16S rRNA sequencing, they found there
was an α-defensin-dependent change in the composition of the
microbiota, such that there was a correlation between α-defensin
deficiency, decreased populations of bacteria from the phylum
Bacteroidetes, and increased populations of bacteria from the
phylum Firmicutes (35). Moreover, in DEFA5 transgenic mice,
there was a loss of segmented filamentous bacteria and interleukin 17 (IL-17)-producing lamina propria T cells, substantiating
the role of α-defensins and thus, Paneth cells in influencing the
microbiota of the gut and modulating the intestinal immunologic
response to pathogens (35).
The role of Paneth cells in disease has been well characterized
in the studies on inflammatory bowel disease (IBD), specifically
ileal Crohn’s disease (36). There are several susceptibility genes
associated with Crohn’s disease, such as nucleotide-binding
oligomerization domain-containing protein 2 (NOD2), which is
expressed predominantly by Paneth cells in the small intestine
(37–39). One such study evaluated known NOD2 loss-of-function
gene mutations known to be risk factors for IBD in a group of
very low birth weight infants (40). They found that the presence
of two or more NOD2 genetic risk factors was an independently
associated with the development of NEC and focal intestinal
perforation (40). Moreover, NOD2-deficient mice develop ileal
granulomatous inflammation in response to inoculation with
Helicobacter hepaticus characterized by increased inflammatory
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cytokines and expression of Th1-related genes (41). This was
restored with transgenic expression of α-defensin in Paneth
cells (41). Moreover, in ileal Crohn’s disease, there is decreased
expression of α-defensins, suggesting a relationship between the
secretion of α-defensins by Paneth cells and the pathogenesis of
Crohn’s disease. The involvement of Paneth cells in mediating
protection against NEC is not well defined. However, animal
models utilizing a Paneth-cell depletion method in the presence
of Klebsiella pneumoniae have been shown to produce NEC-like
intestinal injury, suggesting Paneth cells may have a role in NEC
pathogenesis (42–44).

Enteroendocrine Cells

Enteroendocrine cells encompass several cell types that are
located throughout the gastrointestinal system and primarily act
to secrete hormones in response to food stimuli (45). The role
of enteroendocrine cells in the promotion of mucosal immunity
is incompletely understood; however, there is interplay between
the immune system and enteroendocrine cells (46). For example,
enteroendocrine cells express TLRs, and accordingly, can release
chemokines and defensins in response to bacterial antigens, suggesting these cells have a role in the maintenance of intestinal
homeostasis with respect to bacterial colonization (47, 48).
Interaction with the gut microbiota is not limited to the expression of TLRs by enteroendocrine cells. Rather, there are several
mechanisms by which these cells cooperate with the microbiota
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(49). For example, L cells are a subset of enteroendocrine cells that
secrete glucagon-like peptides 1 and 2 (GLP-1 and GLP-2) (45).
Short-chain fatty acids (SCFAs) derived from gut microbiota can
activate specific receptors of L cells, thereby influencing energy
metabolism and gut barrier function via secretion of GLP-1 and
GLP-2 (49). Accordingly, enteroendocrine cells have a unique
interaction with the gut microbiota.
Furthermore, enteroendocrine cells have also been implicated
in IBD. Friedrich et al. (50) found that patients have elevated
serum and colonic pro-inflammatory IL-17c and discovered that
enteroendocrine and to a lesser extent goblet cells were the main
producers of IL-17c. This demonstrates a relationship between
the neuroendocrine system of the gut and the Th17 pathway of
the immune system (50). Nonetheless, more studies are necessary
to understand the role of enteroendocrine cells during intestinal
inflammation and more specifically NEC.

T cells. In one study, NEC was induced in recombination activating gene 1-deficient (Rag1–/–) mice, which lack functional T
and B cells (58, 59). Compared to wild-type counterparts, these
animals exhibited significantly decreased intestinal injury and
mucosal cytokine production, suggesting they are protected
from NEC development (59). Demonstrating that these cells
have a causative role in NEC pathogenesis, susceptibility to NEC
was restored with the adoptive transfer of naïve CD4+ T cells
(59). Furthermore, recruitment and differentiation of T cells
were found to be mediated by activation of TLR4 via cognate
chemokine ligand 25 (59). Thus, this study demonstrates the
principal role of immune cells in NEC, specifically CD4+ T cells,
and their relationship to TLR4 signaling.

Relationship between Tregs
and Th17 Cells

The roles of immune cells in NEC are dynamic, and there is
an imbalance of immune cells that favor a exaggerated proinflammatory state. This is remarkably demonstrated by the
relationship between Tregs and Th17 cells. Forkhead box P3
(Foxp3)-expressing Treg cells are essential for the maintenance
of a stable equilibrium in the gut (57, 60). Tregs are important in
counterbalancing inflammation and promoting antigen-specific
IgA responses so as to maintain commensalism with gut microbiota (57, 61). In humans, intestinal Tregs are present as early
as 23 weeks of gestation, suggesting an early role in intestinal
homeostasis (60). In the intestinal lamina propria of both mice
and premature infants with NEC, there is decreased production
of Tregs and increased production of CD4+ Th17 cells mediated
by STAT3 (59). Additionally, expression of the IL-17 receptor,
IL-17RA is significantly increased in a TLR4-mediated manner
(59). Importantly, IL-17 release by CD4+ Th17 cells results in
intestinal mucosal injury, as demonstrated by impaired enterocyte
tight junctions, increased enterocyte apoptosis, and decreased
enterocyte proliferation, all of which are hallmark features of
NEC (59). Similarly, in a study analyzing the T cell populations in
human NEC, there was decreased Foxp3+ Tregs relative to effector
T cells compared to controls, which correlated with a mucosal
cytokine expression profile indicative of inhibited Treg expression (62). With NEC resolution, Treg cell populations recovered,
suggesting either the inflammatory response observed in NEC
decreases Treg populations acutely or inflammation is attenuated
as Treg populations increase with mucosal healing (62).
The premature human gut is notable for increased expression of
pro-inflammatory cytokines, specifically IL-6, which is involved
in T cells differentiating toward a Th17 phenotype during NEC
development (59). Importantly, in a mouse model of NEC, oral
administration of all-trans retinoic acid (ATRA), which binds
to the nuclear retinoic acid receptor to stabilize transcription of
Foxp3 and repress transcription of RAR-related orphan receptor
γt, resulted in decreased NEC severity, increased Tregs, decreased
CD4+ Th17 cells, and attenuation of IL-17 expression (59). This
suggests that the Tregs serve to provide a protective role in intestinal homeostasis, which is disrupted in NEC.
Further studies demonstrated that Th17 recruitment and Treg
depletion resulted in apoptosis of Lgr5+ intestinal stem cells within
the crypts of Lieberkühn in an experimental model of NEC (63).

Tuft Cells

Finally, there is a unique cell type of the intestinal epithelium called
tuft cells, which are thought to be taste-chemosensory cells found
in both the respiratory tract and gastrointestinal tract (51, 52).
Tuft cells were initially identified by electron microscopy due to
their unique morphology with their tubulovesicular system and a
tuft of long, blunt microvilli (51, 52). There is increasing evidence
for tuft cell involvement in immunity (53). More specifically,
there is a newly discovered role of tuft cells in parasitic infections,
whereby, they generate type 2 helper T cell responses to promote
immunity against such infections (54–56). This is accomplished
by the ability to secrete IL-25 in a transient receptor potential
cation channel subfamily M member 5 (Trpm5)-dependent
mechanism (51, 54–56). IL-25 promotes the expansion of type 2
innate lymphoid cells, an important source of IL-13 (56). This is
crucial because IL-13 acts to promote differentiation of both tuft
and goblet cells contributing to the “weep and sweep” response
of the intestine to parasitic helminth infections, which consists of
goblet cell hyperplasia and increased smooth muscle contractility
(56). Although there is currently no known role of tuft cells in
the pathogenesis of NEC, these studies provide evidence that
these cells are actively involved in the mucosal immunity of the
intestine in addition to their chemosensory roles.

Immune Cells

Immune cells that compose the innate and adaptive immunity
of the intestine exist in the epithelium and lamina propria (57).
The epithelium houses intraepithelial lymphocytes (IELs) and the
cytoplasmic extensions of DCs that interdigitate between epithelial cells (23, 57). Several cell types inhabit the lamina propria,
including but not limited to DCs, macrophages, neutrophils,
immunocompetent T and B cells, and T regulatory cells (Tregs)
in addition to mesenchymal cell types, such as endothelial cells
(23, 57). We will now discuss the various immune cells implicated
in NEC, including T cells, Tregs, Th17 cells, IELs, B cells, macrophages, and DCs.

T Cells

There is increasing evidence that immune cells have a primary
role in the development of NEC, including but not limited to
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After exposure to recombinant IL-17, enteroids derived from
intestinal stem cells exhibited decreased proliferation, decreased
differentiation, and increased apoptosis (63). In addition, depletion of Tregs led to increased intestinal crypt apoptosis, exacerbating the experimental murine NEC model (63). Importantly,
these effects were reversed upon administration of ATRA with
its ability to modulate lymphocyte populations toward a protective Treg phenotype (63). This highlights the potential use of
retinoic acid as a therapeutic in the treatment and prevention of
NEC. Taken together, NEC is an immune cell-mediated disease
defined by an imbalance of lymphocytes shifted toward a Th17
cell phenotype with a decrease in Tregs, which is destructive in
this specific setting.

displayed increased colonization of draining lymph nodes with
bacteria, specifically aerobic bacteria and the opportunist pathogen Ochrobactrum anthropi (72). At both weaning and adulthood,
there were significant differences in the gut microbiota and the
pattern of epithelial gene expression of the intestine, including
genes associated with IBD, between these mice compared to mice
exposed to sIgA (72). Accordingly, exposure to sIgA in breast
milk promotes intestinal homeostasis in the neonatal period with
long-term implications (72). Taken together, IgA is important in
intestinal immunity, and maternal IgA is crucial given the immaturity of the immune system during the neonatal period.

Macrophages

Macrophages are important phagocytic and bactericidal cells of
the immune system. Macrophages are activated after exposure
to lipopolysaccharide (LPS) and interferon-γ, which then release
pro-inflammatory cytokines and nitric oxide (57). To counteract
excessive inflammation, intestinal macrophages are inhibited by
tumor growth factor-β (TGF-β) (57) and have been implicated
in NEC pathogenesis (73). Intestinal macrophages from healthy
term infants have increased phagocytic and bactericidal activity
as well as minimal inflammatory cytokine production when
exposed to bacterial products, which is attributed to the antiinflammatory effects of transforming growth factor β2 (TGF-β2)
(73). In contrast, the phenotype of macrophages during NEC is
strongly inflammatory as demonstrated by increased expression
of the gene, mothers against decapentaplegic homolog 7 (Smad7),
an inhibitor of TGF-β2 (74, 75). Consequently, this interrupts
TGF-β-mediated downregulation of the pro-inflammatory
response by macrophages in NEC and thereby sensitizes macrophages to bacterial products, leading to a significant proinflammatory response (74). Taken together, the imbalance of
macrophage effector responses toward an inflammatory state
increases mucosal injury in NEC.

Intraepithelial Lymphocytes

Intraepithelial lymphocytes are a group of heterogeneous
lymphocytes of the innate immune system in the distinctive
position to interact dynamically with the local gut environment
and the mucosal adaptive immune system to maintain intestinal
homeostasis (64). This unique population of IELs bears the T cell
receptor γδ (65). They differ from TCRαβ T-cells in that they do
not require antigen processing for effector function (65). They
are important in the discussion of the infant gut due to their
early development in embryogenesis (66, 67). IELs are involved
in a multifaceted approach in the maintenance and repair of the
epithelium through tight junction preservation, recognition of
stressors, and regulation of inflammation (65). They are also
involved in a dynamic cross talk with commensal bacteria, as
commensal bacteria direct expression of key immunomodulatory
and antibacterial responses by influencing gene transcription of
IELs, while IELs prevent opportunistic commensal bacteria overgrowth in the setting of mucosal injury (68). Weitkamp et al. (66)
determined that γδ IELs are the predominant IEL subtype in the
immature intestine of mice and premature infants. Furthermore,
they showed that in the intestine of infants with NEC, there
was a reduction in the γδ IEL subset as compared to non-NEC
controls (66). This study highlights the important role of γδ IELs
in intestinal barrier protection and suggests a potential cellular
target for NEC prevention.

Dendritic Cells

Dendritic cells are specialized APCs that have the delicate role of
mediating protective adaptive immunity in response to pathogens
while maintaining intestinal homeostasis and commensal bacteria (76). Although they are important in intestinal immunity, the
role of DCs in NEC has not been fully elucidated. However, in
one study using Cronobacter sakazakii to induce NEC in newborn
mice, DCs were recruited from the lamina propria, resulting in
intestinal barrier dysfunction via tight junction disruption and
increased enterocyte apoptosis via TGF-β production (77).
The study concluded that the presence C. sakazakii was able to
modulate the activity of DCs to increase TGF-β production,
which subsequently resulted in damage to the mucosal barrier
integrity (77). This highlights the sensitive interaction between
DCs and bacteria, which can be detrimental in the setting of
NEC; however, more studies are necessary to further understand
the role of DCs in NEC pathogenesis.

B Cells and Immunoglobulins

B cells are both important antigen-presenting cells (APCs) and
integral members of adaptive immunity with their ability to
secrete immunoglobulins as plasma cells, most notably IgA in
the context of neonatal immunity. IgA can neutralize pathogenic
bacteria to maintain intestinal homeostasis (9). The maternal IgA
from colostrum and milk is an important source of immunity
in the neonatal period. Secretory IgA (sIgA) is detected weeks
after birth and increases progressively; however, preterm infants
have decreased concentrations of sIgA compared to full-term
infants (69, 70). One study found higher levels of sIgA from the
colostrum and milk of mothers of preterm infants, suggesting
immunological adaptation occurs in the setting of prematurity to
enhance immunity with IgA and reinforces the benefits of breastfeeding in this context (71). There are both early and long-term
benefits of early exposure to maternal sIgA (72). In one study,
they found weanling mice exposed to sIgA-deficient breast milk
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Neutrophils

Neutrophils are important effector cells of the innate immune system distinguished by their ability to respond rapidly and robustly
to tissue trauma, including the intestine. The role of neutrophils
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in NEC pathogenesis has not been fully elucidated, but there are
several studies to note. Small for gestational age (SGA) neonates
are more likely to have neutropenia during the first few days after
birth, and these infants with neutropenia were at increased risk for
developing NEC compared to SGA infants without neutropenia
(78). Moreover, in a model of C. sakazakii-induced experimental
NEC, depletion of neutrophils and macrophages in the lamina
propria resulted in increased production of pro-inflammatory
cytokines and increased enterocyte apoptosis, thereby exacerbating the disease (79). This suggests both macrophages and
neutrophils are important in early infection and their absence
intensifies the inflammatory response observed in NEC. One
study utilizing TNBS-induced enterocolitis to model NEC found
the leukocyte infiltrate relatively devoid of neutrophils in the
intestinal tissue (80). Taken together, impairment of neutrophil
function is one component of NEC; however, more studies are
necessary to determine whether this is a primary observation in
NEC or secondary to the disease.

TLRs are expressed by intestinal epithelial cells and immune
cells of the lamina propria and are involved in epithelial cell
proliferation, IgA production, maintenance of tight junctions,
and AMP expression (23, 57, 83). TLR4 is of specific interest in
the understanding of NEC pathogenesis, as its overexpression in
the setting of prematurity yields a significant pro-inflammatory
response and dysfunction of the epithelium (84). TLR4 is
expressed by intestinal epithelial cells (85), which we will discuss
in greater detail with respect to epithelial TLR4 expression and
the development of NEC.
However, other TLRs have also been implicated in NEC
pathogenesis. For example, TLR2 is expressed throughout the
intestinal epithelium, including enterocytes, as well as various
immune cells found in the lamina propria. Gram-positive bacteria in the intestine can engage TLR2, which can induce MyD88,
which is a major adaptor for TLR2/TLR4, with subsequent NF-κB
activation (86). TLR2 through the regulation of tight junctions is
able to maintain gut barrier integrity, and thus, its deficiency can
predispose the intestine to stress-induced injury (86). The role of
TLR2 in NEC has not been fully elucidated thus far. However, in
a rat model of NEC, investigators have found upregulation of ileal
TLR4 and TLR2 in several studies, which precedes histological
evidence of mucosal injury, suggesting a causative role in NEC
pathogenesis (87, 88). Moreover, certain therapeutic interventions that reduced NEC severity in animal models downregulated
the expression of TLR2 and TLR4, including glutamine (88) and
probiotic Bifidobacterium (89). Thus, aberrancy in TLR4 signaling is not solely responsible for the pro-inflammatory response
observed in NEC.
Moreover, NOD1 is also expressed by intestinal epithelial cells,
which in response to the Gram-negative bacterial peptidoglycan,
elicits an immune response to induce the formation of gutassociated lymphoid tissue, specifically Peyer’s patches (9, 57).
Conversely, NOD2 is expressed highly by monocytes and Paneth
cells at baseline, and by enterocytes when under stress (9, 57).
NOD2 is important in the cross talk between T-cells and intestinal epithelium to downregulate inflammation by inhibiting TLR
signaling (9, 57). One study demonstrated that NOD2 activation
inhibited TLR4 in enterocytes, thereby decreasing enterocyte
apoptosis and attenuating the severity of experimental NEC (90).
In this study, NOD2 provided protection from TLR4-mediated
enterocyte apoptosis via a novel SMAC-diablo pathway (90). This
suggests that modulation of this cross talk may provide a potential
means of decreasing NEC severity (83, 90). Furthermore, NOD2
is important in regulating commensal bacteria such that NOD2deficient mice had decreased ability to prevent colonization by
pathogenic bacteria in the intestine (91). Conversely, germ-free
mice had significantly decreased NOD2 expression, but this
expression was inducible with the introduction of commensal
bacteria, demonstrating the feedback mechanism by which
NOD2 regulates the gut microbiota (91). Upon ligand binding,
both NOD1 and NOD2 activate NF-κB, and independently function by activating this signaling pathway, but can also modulate
TLR4 signaling in this way (92). Thus, TLR and NOD signaling
exemplify the delicate interaction between luminal bacteria and
the innate immune system of the gut and how perturbations in
these pathways may lead to NEC development.

Peyer’s Patches

Peyer’s patches are unique structures found primarily in the distal
intestine that serve as secondary lymphoid tissue. Compared to
other secondary lymphoid tissues, Peyer’s patches are distinguished
by their significant exposure to a diverse group of antigens, from
the gut microbiota to food antigens (81). Antigens are delivered
by M cells of the epithelium, and upon activation, generate B cells
and plasma cells to maintain mucosal immunity (81). Peyer’s
patches appear in the intestine at 11 weeks, but continue to develop
throughout gestation (82). Moreover, their numbers increase in
proportion to gestational maturation, and thus, premature infants
have less Peyer’s patch numbers and decreased maturation (82). It
is unknown if this has clinical significance in the setting of NEC.
Accordingly, more studies are necessary to determine if Peyer’s
patches have a role in NEC as a consequence of prematurity.

CELL SIGNALING
The innate immune system of the intestine is intricately involved
in the pathogenesis of NEC. An important aspect of the innate
immune system is the expression of PRRs, including TLRs and
NOD proteins, that can interact with the local gut environment
and initiate several signaling pathways. We will review these
essential components and their cellular responses with specific
attention to aberrant TLR4 signaling, which is well studied in the
pathogenesis of NEC.

PRRs: TLR and NOD

Pattern-recognition receptors are expressed throughout the cells
of the body as a means of detecting threats to local homeostasis.
The cells of the intestinal epithelium and immune cells express
TLRs and NOD proteins, which can detect pathogen-associated
molecular patterns such as the LPS of Gram-negative bacteria
and flagella and consequently initiate an appropriate response to
these bacterial stressors (23).
Specifically, in the case of TLR4 activation, signaling results
in nuclear factor-κB (NF-κB) activation, subsequent cytokine
production, resulting in an acute inflammatory response (23).
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TLR4 Signaling

Genetic Risk Factors

One of the major cornerstones in understanding the development
of NEC is the role that TLR4 signaling plays in the pathogenesis
(59, 85, 93–100). Activation of TLR4 within the intestinal epithelium in the setting of prematurity results in decreased enterocyte
proliferation, increased enterocyte apoptosis, disruption of
intestinal barrier integrity, and bacterial translocation, resulting
in a systemic inflammatory response (26, 84, 95, 97). As a result
of bacterial translocation, TLR4 is activated on the endothelium
of premature gut, leading to impaired blood flow and subsequent
intestinal ischemia via reduction of endothelial nitric oxide
synthase (eNOS) (100, 101). The differential response to stress
between premature and full term neonates rests in the increased
expression of TLR4 in prematurity (96). TLR4 is expressed at
high levels in the developing intestine as it is involved in normal
gut development in both mice and humans (8). In the setting of
prematurity, TLR4 expression remains elevated, resulting in a
hyper-active, exaggerated response to stressors upon colonization by bacteria (8).
Furthermore, TLR4 is necessary for the development of NEC,
and its enhanced expression is not a consequence of the disease.
In studies utilizing TLR4-mutant mice strains (C3H/HeJ mice),
lack of functional TLR4 was protective against the development
of NEC, such that wild-type mice had increased NEC severity,
increased enterocyte apoptosis, reduced enterocyte proliferation,
and impaired restitution compared to TLR4-mutant mice (97).
These results were further supported utilizing mice with either
global TLR4 deletion or intestinal-specific TLR4 deletion (26).
Both groups of mice were protected from the development of
experimental NEC with preservation of mucosal integrity and
minimal elevation of pro-inflammatory cytokines (26). These
studies highlight the causative role of aberrant TLR4 signaling
expressed by IECs in NEC pathogenesis.
Aberrant TLR4 signaling also has a direct role in the breakdown of the gut barrier in NEC. In healthy mucosa, healing of the
epithelium occurs in two phases, intestinal restitution followed
by enterocyte proliferation, whereby healthy IECs migrate to
injured mucosa followed by increased generation of IECs from
stem cells of the intestinal crypts (18). TLR4 signaling impairs
IEC migration, thus impairing restitution (102, 103). Moreover,
enterocyte proliferation is significantly decreased in NEC, diminishing the ability to heal in the setting of mucosal injury (18, 95,
97–99). Importantly, autophagy is a response to cellular stress and
has been found to be upregulated in NEC (104). Furthermore,
TLR4 signaling induces autophagy of enterocytes in both mouse
and human studies (105). An experiment utilizing intestinal
epithelial-specific autophagy gene ATG7 conditional knockout
mice demonstrated autophagy via ATG7 was required for NEC
development as these mice were protected from NEC (105).
TLR4-induced autophagy leads to impaired enterocyte migration,
demonstrating the effects of TLR4 signaling on the epithelium are
multifaceted and interconnected (105). Ultimately, the deficiency
in mucosal repair via enterocyte restitution and proliferation in
the setting of NEC weakens the integrity of gut, allowing for bacterial translocation and the downstream inflammatory response
observed in this disease.
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The study of genetic risk factors in NEC is an important component in understanding the signaling pathways that involve
the innate immune system. There are several genetic association
studies evaluating the relationship between specific genetic risk
factors and the development of NEC (106). Genetic variation
that affects TLR signaling increases the predisposition of the premature intestine to inflammatory aberrancy. The gene SIGIRR is
important in the inhibition of LPS-induced inflammation (107).
Loss-of-function mutations of SIGIRR result in unregulated TLR
signaling, thereby predisposing infants to NEC (107). One study
specifically evaluated the roles of single nucleotide polymorphisms
of important genes in TLR signaling. They found in studying the
blood samples of very low birth weight infants a relationship
between NFKB1 and NFKBIA variants and the development of
NEC, such that NFKB1 increased susceptibility to NEC, whereas
NFKBIA decreased susceptibility to NEC (108). However, there
was no association between TLR2, TLR4, TLR5, TLR9, IRAK1,
and TIRAP genes and the development of NEC in this patient
population (108). Genetic risk factors for NEC have not just been
limited to TLR and NOD signaling pathways. For example, one
study evaluating the autophagy gene ATG16L1 in premature
infants found that hypomorphic variants conferred protection for
the development of NEC (109). This study highlights the breadth
of possible genetic risk factors in the NEC. Taken together, genetic
predisposition to NEC is valid, and further large scale studies will
likely reveal more genetic relationships and disease development.

GUT MICROBIOTA
The intricate relationship between gut microbiota and mucosal
immunity is central to the discussion of NEC pathogenesis. The
gut is exposed to a multitude of microbes, and it is the role of
the intestinal immune system to distinguish commensal bacteria
from pathogenic bacteria, particularly as the gut flora develops
early in life. There are several variables that influence the microbial composition of the intestine; however, new evidence suggests
that disruption of normal bacterial flora is involved in NEC
pathogenesis. We will now explore the role of gut microbiota in
the setting of prematurity.

Factors Influencing Gut Microbiota

There is a significant interest in understanding the composition
of the gut microbiota and its relationship to the pathogenesis of
NEC. Several factors influence the neonatal microbiota, including
gestational age, mode of delivery (vaginal vs. cesarean section),
antibiotic treatment, and diet (breast milk vs. formula feedings)
(110). Colonization occurs in two waves, and the first wave is
dependent on the mode of delivery (111). For example, one study
found that compared to infants born vaginally, infants born via
cesarean section had decreased populations of Bifidobacteria
and Bacteroides, while there was an increased population of
Clostridium difficile (112). The second wave is dependent on
feeding method, which often differs between premature and
term infants, as breast milk and formula feedings have different
bacterial compositions and access to breast milk can be limited in
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prematurity with delayed initiation of enteral feeding in preterm
newborns (113). More specifically, formula-fed infants have
increased populations of Enterobacteriaceae, Bacteroides species,
and C. difficile in the stool compared to infants fed breast milk
(112, 114).
Moreover, duration of antibiotic exposure is associated with
the development of NEC (115, 116). In one retrospective study
investigating the association between antibiotic exposure and
subsequent diagnosis of NEC in infants, they found that antibiotic
exposure duration is associated with increased risk of developing
NEC (115). When sepsis was eliminated as a potential confounder,
the probability of developing NEC was increased 20% per day of
antibiotic exposure (115). Strikingly, antibiotic exposure greater
than 10 days in neonates resulted in an approximately threefold
increased risk of developing NEC (115). Another retrospective
study aiming to assess the association between initial antibiotic
therapy in extremely low birth weight infants and NEC, found
there was an increased risk of developing NEC after initial
empiric antibiotic treatment in the first three postnatal days (116).
Empiric antibiotic treatment for greater than 5 days, which the
study defined as prolonged antibiotic treatment, was associated
with the development of NEC and death in extremely low birth
weight infants in the setting of sterile blood cultures (116). These
studies highlight the need to be judicious in the implementation
of empiric antibiotic treatment in preterm infants.
A recent study utilizing 16S rRNA gene pyrosequencing suggests the most important variable influencing the composition of
premature gut microbiota is the degree of prematurity (117). Using
922 specimens from 58 subjects, they found an ordered, tightly
controlled microbial progression of bacterial classes: Bacilli to
Gammaproteobacteria to Clostridia (117). Other factors, including antibiotics, mode of delivery, and age influenced the pace of
the progression of bacterial classes, but the particular sequence
of development remained the same (117). This is important as
more studies demonstrate the significance of dysbiosis and the
development of NEC (113, 118–122).

decreased quantities of Negativicutes and Clostridia in infants that
went on to develop NEC, with the strongest correlation between
bacteria composition and development of NEC occurring prior
to 27 weeks gestation (127). This study suggests an increased concentration of Gram-negative facultative bacteria is detrimental,
possibly due to their ability to activate TLR4 via LPS (84, 122).
Conversely, infants with NEC had significantly decreased obligate
anaerobes (127), which interestingly produce anti-inflammatory
SCFAs (128). These results suggest that interventions focused on
modulation of the gut bacteria may play a role in preventing NEC.

PROTECTIVE STRATEGIES AGAINST NEC
With advancements in our knowledge of NEC, there are several
potential preventative and therapeutic strategies that did not exist
decades ago. We will review several of these strategies with respect
to how they influence the intestinal immune system (Figure 2).
These advancements target several aspects of the intestinal
immune system, such as TLR4 signaling modulation, gut barrier
integrity, immune cell composition, and the gut microbiota, all
of which have been described with their individual roles in NEC.
There have been several studies that demonstrate the importance
of providing breast milk to premature infants instead of formula.
Human breast milk contains several bioactive components
beneficial to the neonate some of which include: epidermal
growth factor (EGF), heparin-binding EGF-like growth factor,
platelet-activating factor (PAF) acetylhydrolase, human milk
oligosaccharides (HMOs), nitrates/nitrites, l-arginine, lactoferrin, and probiotics (8, 129, 130). We will review several breast
milk components and the evidence supporting the mechanisms
by which they impact the intestinal mucosal immunity during
NEC. We will also discuss the use of antenatal corticosteroids and
delayed umbilical cord clamping in the prevention of NEC.

Breast Milk

Breast milk has a well-established role in the prevention of NEC
and clinically represents one of the most effective strategies in
decreasing the incidence and progression of NEC (130). New preclinical evidence has demonstrated that breast milk is capable of
attenuating the TLR4-mediated pro-inflammatory response integral to NEC pathogenesis by activating the receptor for epidermal
growth factor (EGFR), revealing the interplay between the EGF
pathway and the hallmark TLR4 signaling of NEC (95). These
inhibitory effects on TLR4 signaling were mediated by breast
milk preventing the activity of the downstream target glycogen
synthase kinase 3β, resulting in enhanced mucosal healing, intestinal stem cell proliferation and decreased enterocyte apoptosis
(95). In seeking to determine the particular component in breast
milk that mediated the protective effects, when EGF was either
removed or its receptor, EGFR was inhibited, the protection on
experimental NEC and TLR4 signaling was abolished (95). Taken
together, these mechanistic studies describe one of the ways breast
milk protects the intestinal epithelium against NEC.

Dysbiosis in NEC

The differences in microbial colonization between preterm
infants and term infants suggests the possible role of dysbiosis on
the pathogenesis of NEC. The onset of NEC occurs 2–6 weeks of
life with the highest risk of NEC occurring at a corrected age of
29–33 weeks (123), only after microbial colonization of the gut
(2, 124, 125), highlighting the role of gut microbiota in disease
pathogenesis. To date, no specific microbial pathogen has been
identified to be responsible for the development of NEC (119,
124, 125). However, resected intestinal tissue with active NEC
demonstrated increased microbial burden and an abundance of
strict anaerobes with a decrease in community diversity (126).
Moreover, until recently, it was unclear if abnormal gut microbiota is a cause or consequence of NEC (127). A prospective
case–control study by Warner et al. (127) helps to define the role
that the microbiota plays in NEC development. In 166 very low
birth weight infants, 3,586 stool samples were prospectively collected, and of these subjects, 46 developed NEC (127). Differences
between the NEC cases and matched controls emerged after
1 month with a predominance of Gammaproteobacteria and
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Several other studies have looked at the protective role of EGF itself
against NEC. In a neonatal rat model of NEC, administration of
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Figure 2 | Mechanisms of protective strategies in necrotizing enterocolitis (NEC). (A) The enterocyte is the predominant cell type of the epithelium and
significantly contributes to the exaggerated pro-inflammatory response observed in NEC upon activation of toll-like receptor 4 (TLR4) by Gram-negative bacteria
lipopolysaccharide (LPS). TLR4-mediated activation of nuclear factor-κB (NF-κB) results in increased expression of pro-inflammatory cytokines, such as IL-1, IL-6,
and TNF-α. However, this signaling pathway can be attenuated through various mechanisms. Epidermal growth factor (EGF), which is found in breast milk and
amniotic fluid, inhibits this pathway via inhibition of glycogen synthase kinase-3 beta (GSK3β). The human milk oligosaccharide 2′-fucosyllactose (2′FL) also
attenuates the TLR4 pro-inflammatory signaling pathway. Finally, intracellular pattern recognition receptor nucleotide-binding oligomerization domain-containing
protein 2 upon stimulation by pathogen associated molecular patterns via second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding
protein with low pI (SMAC-diablo). (B) Endothelial cells have an integral role in the pathogenesis of NEC. Endothelial cells express TLR4, and upon stimulation by
LPS following gut barrier dysfunction, decrease the expression of endothelial nitric oxide synthase (eNOS), thereby reducing the formation of nitric oxide (NO), an
important vasodilator. This results in intestinal ischemia and subsequent NEC. However, several protective strategies increase the production of NO, including
heparin-binding EGF-like growth factor (HB-EGF) and 2′FL by increasing expression of eNOS. Nitrates (NO3− ) and nitrites (NO2− ) can be found in breast milk and are
precursors to NO, thus increasing NO production. Finally, l-arginine is required for NOS-dependent formation of NO. Supplementation with HB-EGF, nitrates, nitrites,
and l-arginine are protective in NEC with their ability to improve intestinal blood supply via NO-mediated vasodilation.

EGF alone reduced both the incidence and severity of the disease
(131). EGF administration resulted in significantly decreased
epithelial permeability, normalized expression of tight junction
proteins, increased goblet cells (28), and inhibited enterocyte
apoptosis (132), all of which are protective hallmarks in NEC
(26, 59, 95). Moreover, another mechanism by which EGF provides protection against NEC is inhibition of autophagy (133),
a lysosomal pathway of self-digestion that has been shown to
be activated in mice and infants with NEC (105). Additionally,
a recent study demonstrates that a hypomorphic variant in an
autophagy-related gene, ATG16L1 is associated with NEC in
premature infants (108). This further underlies the importance
of determining which infants are the most susceptible to NEC, so
that protective strategies including EGF administration may be
tailored to those individuals.

fluid have been described in experimental NEC models in several
species including neonatal mice (94), rats (134), and piglets (135).
Other investigators have examined amniotic fluid outside the setting of EGF in the study of NEC. In a neonatal rat model of NEC,
administration of amniotic fluid stem cells attenuated NEC by
increasing enterocyte proliferation and decreasing apoptosis in a
cyclooxygenase 2 dependent mechanism (136). In other studies,
the administration of amniotic fluid resulted in differences in
gut microbiota and reduced intestinal permeability compared to
controls (137). Taken together, the ingredients in both breast milk
and amniotic fluid provide important protective mechanisms to
counter-regulate the detrimental pro-inflammatory effects in the
intestine afflicted by NEC.

Heparin-Binding EGF-Like Growth
Factor (HB-EGF)

Amniotic Fluid

Heparin-binding EGF-like growth factor is found in breast milk
and amniotic fluid and provide numerous protective effects in
models of intestinal injury and NEC (138). In mice, overexpression of the HB-EGF gene is protective against the development of
NEC (139), whereas deletion of HB-EGF increases susceptibility
to experimental NEC (140). As described previously, an important
component in the pathogenesis of NEC is the disruption of gut
perfusion and decreased expression of the vasodilatory molecule
eNOS (100). In neonatal mice subjected to experimental NEC,

As discussed above, EGF administration mediates several protective effects on the intestine and is found in breast milk as well
as amniotic fluid. We demonstrated that amniotic fluid inhibited
TLR4-mediated inflammatory signaling in the fetal and neonatal
intestinal epithelium in a manner dependent on EGFR (94).
Intestinal EGFR expression was low in premature infants with
NEC compared to that of a fetus or at the time of reanastamosis
after NEC had resolved (94). The protective effects of amniotic
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impairment of intestinal microvascular blood flow was improved,
and there was decreased epithelial injury with administration of
HB-EGF (141). Moreover, HB-EGF promotes angiogenesis with
upregulation of eNOS and subsequent production of nitric oxide
via the PI3K pathway (142, 143).
Heparin-binding EGF-like growth factor is also unique
in its ability to modulate the intestinal immune system. For
example, there are subtypes of macrophages, which can either
be pro-inflammatory (M1) or anti-inflammatory (M2) (144).
Macrophage infiltration in NEC was marked by a predominance of M1 pro-inflammatory macrophages and treatment
with HB-EGF resulted in increased M2 anti-inflammatory
macrophages, thereby protecting against experimental NEC.
Moreover, HB-EGF also helps in maintaining gut barrier integrity
with increased enterocyte proliferation (145) and migration (146)
as well as decreased apoptosis of enterocytes (147), which is a
common theme among the potential protective strategies in NEC.

colonization in the intestine during the critical neonatal period in
several studies (159–165). In another study, the HMO 2′FL inhibited the release of IL-8 by IECs in the setting of bacterial infection
by attenuating the expression of CD14 (166). However, this effect
was not observed in IECs that were not exposed to the bacterial
pathogen, showing that HMOs are capable of modulating specific
inflammatory pathways during infection (166). Another HMO,
disialyllacto-N-tetraose, was capable of reducing the NEC severity in neonatal rats (167). Taken together, these studies advance
our understanding of the effects of HMOs in preventing against
NEC and may provide a nutritional preventative strategy worth
pursuing.
The breast milk composition of HMOs varies among mothers, which in turn influences the microbiota of their offspring.
Specifically, mothers with inactive alleles of the gene fucosyltransferase 2 (FUT2) are referred to as non-secretor mothers (168), and
this mutation leads to changes of the microbiota of their infants.
Specifically, infants in this setting had delayed establishment of
the genus Bifidobacterium, which are early colonizers in breastfed
infants (168). This suggests HMOs can enrich certain beneficial
populations of bacteria. Moreover, since the individual composition of breast milk varies widely, attention to these details may
provide a novel strategy of personalized breast milk fortification
to prevent NEC in preterm infants.

Platelet-Activating Factor Acetylhydrolase
(PAF-AH)

Platelet-activating factor is a potent phospholipid inflammatory
mediator involved in the pathogenesis of NEC in human and
animal studies (148, 149). Activation results in epithelial cell
damage, increased apoptosis, increased mucosal permeability,
disruption of tight junctions, leukocyte and platelet aggregation, and vasoconstriction, disrupting mucosal integrity (148,
149). Importantly, PAF-AH is capable of catabolizing PAF and
decreases the destructive properties of PAF in the intestine (150).
Additionally, breast milk contains PAF-AH, which is one component in breast milk thought to provide protection against the
development of NEC (150, 151). The clinical relevance of PAF is
demonstrated by the findings that compared to controls, infants
with NEC display increased plasma and stool PAF concentrations
and decreased plasma PAF-AH, which is responsible for PAF
breakdown (152–154). In neonatal mouse and rat models, NEC
susceptibility decreased with inhibition of PAF and increased with
PAF-AH depletion (155–157). Of note, PAF was found to induce
TLR expression in the intestine, providing a connection between
two pathways involved in NEC pathogenesis, thereby suggesting luminal PAF in the preterm intestine may upregulate TLR
expression and subsequently promote a pro-inflammatory state
(158). Taken together, PAF-AH may serve as an important target
by inhibiting intestinal inflammation and epithelial disruption.

Nitric Oxide

One of the hallmarks of NEC pathogenesis is the disruption of
the microcirculatory perfusion to the gut, which is regulated by
endothelial expression of TLR4 (100). Specifically, endothelial
TLR4 signaling impairs intestinal perfusion and decreases eNOS
expression and accordingly nitric oxide (NO), such that mice
with selective endothelial TLR4 deletion exhibited preserved
mucosal integrity and decreased intestinal ischemia (100). In this
context, TLR4 signaling promotes bacterial translocation with
the disruption of the epithelial barrier, intensified by impaired
intestinal perfusion by decreased expression of eNOS with the
activation of endothelial TLR4.
Human breast milk contains sodium nitrate, which is a precursor to nitrite and NO production, a key vasodilatory molecule
involved in maintaining intestinal perfusion (100). Interestingly,
the concentration of sodium nitrate is higher in breast milk as
compared to formula (100), and when compared to adults,
infants in the NICU receive significantly less dietary nitrites and
nitrates (169). Bacterial conversion of nitrates to nitrites first
occurs in saliva, which can then be converted to nitric oxide via
both NOS-independent mechanisms in the stomach and NOSdependent mechanisms in the intestine from the amino acid
l-arginine (170). This illustrates the interaction of bacteria and
the gastrointestinal system and also highlights the importance
of having dietary nitrates and nitrites in the form of breast milk
during the critical neonatal period. This further suggests there
is the opportunity to improve the deficits in dietary nitrites and
nitrates inherent to neonates to prevent NEC. Moreover, studies
have shown that enteral supplementation of l-arginine was not
only safe but was able to reduce incidence and severity of NEC
in very low birth weight preterm infants (171, 172). Accordingly,
l-arginine, nitrates, and nitrites in the neonatal period are not

Human Milk Oligosaccharides

Human milk oligosaccharides are carbohydrates recently heralded
as protective components within breast milk. There are several
means by which HMOs are protective in the setting of NEC. We
recently demonstrated that 2′-fucosyllactose (2′FL) is an abundant HMO that is protective against NEC in mice via modulation
of the vasodilatory molecule, eNOS expression and subsequently
enhancing intestinal perfusion (101), which has been previously
shown to be impaired in NEC (100). Moreover, 2′FL is capable
of attenuating inflammation, and we demonstrated that 2′FL
decreased the expression of several pro-inflammatory markers
including IL-6, IL-1β, inducible nitric oxide synthase, and TLR4
(101). Importantly, HMOs have been shown to influence bacterial
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only important but given their ability to modulate the microcirculation of the preterm intestine, they have utility as a preventative strategy for NEC.

pro-inflammatory response observed in NEC (188). Oral
administration of Lactobacillus rhamnosus HN001 attenuated
NEC severity in both premature piglets and newborn mice and
the mechanism mediating this effect was via TLR9 activation
(189). Lactobacillus reuteri in neonatal mice was able to increase
enterocyte migration, enterocyte proliferation, and crypt height
of the epithelium. This counters the impairment in enterocyte
migration and proliferation that serve as hallmarks of NECmediated gut barrier dysfunction (190). These studies suggest
probiotics are able to interact with the mucosal immunity of
the gastrointestinal tract, thereby offering a viable preventative
strategy in clinical NEC management.

Lactoferrin

Lactoferrin is found in secretory fluids including breast milk and
colostrum, where it acts an important member of mucosal immunity with its antimicrobial properties (173), ability to modulate
the gut microbiota (174), and maturation of the intestine by
inducing enterocyte growth and proliferation (175). Accordingly,
the use of lactoferrin supplementation in preterm infants to prevent complications has been studied. The most recent Cochrane
Review suggests that there is utility in the administration of oral
lactoferrin prophylaxis due to the decrease in the development
of NEC and late-onset sepsis without adverse effects (176–180).
Another study evaluated the use of recombinant human lactoferrin (talactoferrin or TLf) in infants with a birth weight of
750–1,500 mg as means of reducing infection (181). There was
no associated toxicity in the administration of TLf, and there was
a trend toward less infectious morbidity in infants treated with
TLf (181). Thus, lactoferrin administration in low birth weight
infants is a promising preventative strategy against NEC with no
adverse effects reported thus far.

Antenatal Steroids

Corticosteroids are often administered in the antenatal period
to reduce mortality and morbidities associated with prematurity.
Based on a Cochrane Review, the use of a single course of antenatal
corticosteroids is recommended for all women at risk for preterm
birth (191). In addition to accelerating fetal lung maturation,
antenatal corticosteroids are associated with decreased likelihood for the development of necrotizing enterocolitis analyzing
8 studies with 1,675 infants total (191). A more recent clinical
study supports these findings, in which there were significant
differences between infants that received full course antenatal
steroids and infants that did not, such that prompt administration of a full course of antenatal corticosteroids decreased the
incidence of NEC and mortality (192). Presently, it is unknown
the mechanism by which corticosteroids are protective in NEC.
However, with our knowledge of the primary role of immune cells
in the pro-inflammatory response in NEC, corticosteroids serve
as an interest of study with their ability to modulate the immune
system.

Probiotics

Probiotics have generated significant interest in the prevention of
NEC given the increasing data regarding the relationship between
the gut microbiota and disease development. Prophylactic enteral
probiotics show significant promise in the prevention of NEC. A
Cochrane Review concluded probiotics in the setting of prematurity prevent severe NEC and decrease all-cause mortality (182).
A more recent systematic review and meta-analysis utilizing
additional studies supported these findings (183). As probiotics
continue to be investigated, it is important to recognize there is
significant heterogeneity with organisms chosen and dosing regimens across the studies. Bifidobacterium lactis has been studied
in isolation in clinical studies. In a prospective randomized case–
control study, administration of B. lactis-supplemented formula
resulted in decreased intestinal permeability as measured by a
sugar absorption test, suggesting B. lactis is important in maintaining epithelial integrity (184). In another clinical study, B. lactis
Bb12 supplementation influenced the gut microbiota such that
supplementation increased the number of Bifidobacterium spp.
and reduced the number of Enterobacteriaceae and Clostridium
spp., which may be implicated in NEC pathogenesis, in stool
samples of preterm infants (185). It is important to note that the
largest clinical trial for a specific probiotic, Bifidobacterium breve
BBG-001, found no benefit in the administration of this probiotic
in preterm infants to prevent NEC (186). More clinical studies
evaluating the utility of specific organisms within probiotic
regimens are necessary.
Moreover, there are several mechanisms by which probiotics
can prevent the development of NEC (187). Two studies highlight our present knowledge of NEC pathogenesis as related to
mucosal immunology. Bifidobacterium adolescentis is able to
alter TLR4, TOLLIP, and SIGIRR expression in preterm neonatal
rats, suggesting it is able to downregulate the TLR4-mediated
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Umbilical Cord Clamping

There is debate on the optimal interval of time between infant
delivery and umbilical cord clamping in the setting of prematurity. Delayed cord clamping provides more placental transfusion
between the placenta and the newborn, whereas immediate cord
clamping allows for immediate resuscitation of the premature
newborn by a neonatologist (193). A Cochrane Review found
that delayed cord clamping decreased the incidence of NEC (193);
however, larger studies are necessary to evaluate this finding as
well as the long-term effects of immediate vs. delayed cord clamping. In a more recent study, umbilical cord milking, which utilizes
the same principle behind delayed umbilical cord milking also
conferred protection against the development of NEC in preterm
infants (194). The mechanisms by which umbilical cord clamping
and umbilical cord milking provide protection against NEC are
incompletely understood and warrant further investigation.

Immunoglobulins

The roles of B cells and immunoglobulins in the setting of NEC are
not fully understood in the context of disease development and
preventative strategies. A trial of oral immunoglobulins administration has been tried for their presumed immunoprotective
effects as prophylaxis in preterm infants (195). However, based
on a recent Cochrane Review of three randomized trials, there
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is no protective role against NEC with the oral administration of
immunoglobulins in the neonatal period, specifically with IgG or
a combination of IgG/IgA, as these studies did not demonstrate
a significant reduction in NEC incidence (195–198). A trial of
oral IgA alone powered for the prevention of NEC in low birth
weight neonates would be beneficial given the known beneficial
properties of sIgA in breast milk (195). Nonetheless, more studies
are necessary to appreciate the role of IgA in NEC pathogenesis
and as a viable prophylactic or treatment strategy.

mucosal immunity of the intestine. Several aspects are integral to
maintain intestinal homeostasis, and there is no one component
singularly responsible for the development of NEC. Rather, it is
an intricate balance of many variables, which yield numerous
therapeutic potentials in treating and preventing this disease. The
goal of this review was to highlight these recent innovations and
mechanistic insights into how administration of various treatments impacts the intestinal immune system and may alleviate
NEC in premature infants.

CONCLUSION
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